Key result
Carrying at least one mutant AMPD1 allele was associated with significantly greater odds of surviving without cardiac transplantation for ≥5 years in patients with advanced heart failure (OR 8.6; 95% CI 3.05-23.87).
Why the study?
Does the presence of a mutant AMPD1 allele improve survival without cardiac transplantation in patients with advanced congestive heart failure?
Observational (n=223)
Does the presence of a mutant AMPD1 allele improve survival without cardiac transplantation in patients with advanced congestive heart failure?
Odds Ratio: 8.6 (95% CI 3.05–23.87)
The presence of a mutant AMPD1 allele is associated with significantly prolonged survival without the need for cardiac transplantation in patients with advanced heart failure.
No takes yet. Share an insight, caveat, or question.
May support AMPD1 as a prognostic marker in advanced HF; hypothesis-generating and requires prospective validation before any clinical use.
Loh et al. (1999) conducted an observational in Congestive heart failure (n=223). Mutant AMPD1 allele vs. Wild-type AMPD1 allele was evaluated on Surviving without cardiac transplantation ≥5 years after initial hospitalization for CHF symptoms (OR 8.6, 95% CI 3.05-23.87). Carrying at least one mutant AMPD1 allele was associated with significantly greater odds of surviving without cardiac transplantation for ≥5 years in patients with advanced heart failure (OR 8.6; 95% CI 3.05-23.87).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: